Premium
Decrease in clonogenic tumour cells in bone marrow aspirates from multiple myeloma patients due to the incorporation of cyclophosphamide into treatment with vincristine, adriamycin and methyl prednisolone
Author(s) -
Bell J. B. G.,
Millar B. C.,
MontesBorinaga A.,
Joffe J. K.,
Cunningham D.,
Mansi J.,
Treleaven J.,
Viner C.,
McElwain T. J.
Publication year - 1990
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2900080607
Subject(s) - vincristine , cyclophosphamide , medicine , clonogenic assay , prednisolone , concomitant , bone marrow , cfu gm , regimen , multiple myeloma , chemotherapy , gastroenterology , apoptosis , stem cell , biology , haematopoiesis , genetics , biochemistry
A study of 32 patients receiving cyclophosphamide (CY) and verapamil (VER) in addition to the drug combination vincristine, adriamycin and methyl prednisolone (VAMP) was made in which the clinical response and growth of clonogenic myeloma cells (MY‐CFU c ) from bone marrow aspirates were compared. At presentation, MY‐CFU c were grown from 72 per cent (23/32) of the patients. After treatment with CY‐VAMP or VERCY‐VAMP, MY‐CFU c were grown from 25 per cent (8/32) of patients of whom only 50 per cent responded clinically. The overall clinical response rate for patients receiving CY‐VAMP and VERCY‐VAMP was 64 per cent (9/14) and 72 per cent (13/18) respectively of whom 14 per cent in each group achieved complete remission. There was no concomitant increase in normal tissue toxicity as measured by granulocyte–macrophage colony (GM‐CFU c ) formation. Comparison of these data with our previous study of patients receiving VAMP alone, suggests that the addition of CY to the regimen may increase the tumour cell kill. Further clinical studies will determine whether there is a significant increase in the complete remission rate.